Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir for high EBV replication in young adult kidney transplant recipients
2025-524786-25-00Phase 4Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of maribavir in Epstein-Barr virus infection and Kidney allograft status (RTx), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Proportion of patients achieving complete viral clearance after maribavir therapy. Planned start Oct 2026; status: authorised.
02
Drugs
maribavir
03
Conditions
Epstein-Barr virus infectionKidney allograft status (RTx)
Beyond the preview
Go deeper on 2025-524786-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524786-25-00.